Background: Risk stratification in Multiple Myeloma is typically done based on a set of chromosomal abnormalities including translocations and deletions and karyotype abnormalities such as hypodiploidy and hyperdiploidy. Hyperdiploidy has been considered a favorable prognostic factor for survival of Multiple Myeloma patients. Methods: We analyzed data from 48 Multiple Myeloma cases at the King Fahad specialist hospital in Saudi Arabia and detected an array of endpoints including riskassociated cytogenetic endpoints. We analyzed data from 48 Multiple Myeloma cases at the King Fahad specialist hospital in Saudi Arabia and detected an array of endpoints including risk-associated cytogenetic endpoints. We sought to test if and how hyperdiploidy affects the survival outcomes of 14 multiple myeloma patients classified as high or intermediate risk based on cytogenetic abnormalities. Results: Kaplan-Meier survival analysis with a Cox proportional hazards regression model showed that progression-free survival (PFS) of Multiple Myeloma patients was higher (hazard ratio 1.9) in those with hyperdiploidy compared to non- hyperdiploidy group. Overall survival in our study appeared to be unaffected (hazard ratio 1.0) by hyperdiploidy. Survival percentage for hyperdiploidy cases was >50% at the median time point. Conclusion: Our data indicates that hyperdiploidy is a favorable prognostic factor for progression-free survival in Multiple Myeloma. Further studies are warranted to investigate hyperdiploidy subtypes and cytogenetic parameters which may be of value in risk stratification and prognosis of Multiple Myeloma cases.
Hani AlHashmi, Afra Al-Dayel, Dina Soliman, Mohammed Al-Sayegh, Omar Abduljalil, Khalid Al Anezi, Ali Al Matrok, Panayotis Kaloyannidis, Arwa Al Saber, Mahmoud M Kamel and Heba Raslan
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : September 19, 2019